Compare Novartis AG (NVS) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Omnicom Group Inc. — how do they compare? Novartis AG trades at $154.71 (market cap $298.18B), while Omnicom Group Inc. trades at $85.75 (market cap $23.22B). The key difference: Novartis AG is far larger — about 12.8× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (3.78%). Which is the better fit depends on your goals.
| NVS | OMC | |
|---|---|---|
Market Cap | $298.18B | $23.22B |
Sector | Health | Media |
52-Week High | $168.62 | $86.22 |
52-Week Low | $119.31 | $67.27 |
Enterprise Value | $339.50B | $31.30B |
Dividend Yield | 3.02% | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Omnicom Group (OMC) trades at $85.24, up 3.31% today, with a bullish technical outlook supported by moving averages and key resistance at $86. Recent Q2 2026 earnings beat estimates with $2.65 EPS and 6.1% organic revenue growth, though net income margin remains thin at 1.74%. The company maintains a $0.80 quarterly dividend and benefits from post-merger synergies with Interpublic Group.
OMC presents a value opportunity with a low P/S of 0.96 and consensus price target of $107, but high P/E of 230.38 and integration risks post-acquisition warrant caution. Analyst sentiment is mixed with 32% buy ratings, highlighting growth potential against margin pressures and competitive threats in the advertising sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
